Xiaoyu Jiangzhi capsule protects against heart failure via Ca2+/CaMKII signaling pathways in mice
Title
Xiaoyu Jiangzhi capsule protects against heart failure via Ca2+/CaMKII signaling pathways in mice
Creator
Wu, Jianwei
Tan, Yafang
Kang, Dongyuan
Yu, Juan
Qi, Jianyong
Wu, Jiashin
Zhang, Minzhou
Publisher
Elsevier B.V.
Date
2022
Description
Objective Heart failure (HF), a worldwide health condition, is the result of many cardiovascular diseases. The traditional Chinese medicine (TCM) Xiaoyu Jiangzhi capsule (XYC) has long been in use in China to treat hyperlipidemia and inhibit platelet aggregation. This study explores the effects of XYC on heart failure (HF) and its detailed mechanisms.
Results XYC reduced HF, inhibiting the protein expression of CaMKII, but Serca did not change significantly. Moreover, XYC inhibited the peak amplitude of the hCaV1.2 current, depolarizing shifted the activation curve 27.6 mV, and shifted the inactivation curve toward a positive potential 17.6 mV. The fraction recovered from inaction was reduced in XYC group compared with that in CON group.
Conclusion XYC could inhibit ISO-induced HF by reducing the Ca2+/CaMKII signaling pathway in mice.
Results XYC reduced HF, inhibiting the protein expression of CaMKII, but Serca did not change significantly. Moreover, XYC inhibited the peak amplitude of the hCaV1.2 current, depolarizing shifted the activation curve 27.6 mV, and shifted the inactivation curve toward a positive potential 17.6 mV. The fraction recovered from inaction was reduced in XYC group compared with that in CON group.
Conclusion XYC could inhibit ISO-induced HF by reducing the Ca2+/CaMKII signaling pathway in mice.
Source
In Journal of Traditional Chinese Medical Sciences July 2022 9(3):289-297
Language
English
Citation
Wu, Jianwei et al., “Xiaoyu Jiangzhi capsule protects against heart failure via Ca2+/CaMKII signaling pathways in mice,” NEOMED Bibliography Database, accessed April 26, 2024, https://neomed.omeka.net/items/show/12215.